Dogwood Therapeutics (DWTX) Change in Accured Expenses (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Change in Accured Expenses of $187830.0 for Q1 2026, up 202.44% year-over-year from $62104.2 in Q1 2025, and down 37.99% quarter-over-quarter from $302900.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Change in Accured Expenses for 7 consecutive years, with $187830.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 202.44% year-over-year to $187830.0; the TTM figure through Mar 2026 stood at $979470.0 (up 259.92% YoY), while the FY2025 annual figure was $608290.0, up 301.13% from the prior year.
- Change in Accured Expenses eased to $187830.0 in Q1 2026 per DWTX's latest filing, from $302900.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $624746.0 in Q1 2022 and bottomed at -$934660.0 in Q4 2024.
- Historically, Change in Accured Expenses has averaged -$10673.2 across 5 years, with a median of -$35140.0 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 2590.57% in 2024 and fell as far as 2559.82% in 2024.
- Dogwood Therapeutics' Change in Accured Expenses stood at -$434628.0 in 2022, then surged by 91.91% to -$35140.0 in 2023, then tumbled by 2559.82% to -$934660.0 in 2024, then surged by 132.41% to $302900.0 in 2025, then tumbled by 37.99% to $187830.0 in 2026.
- Business Quant data shows DWTX's Change in Accured Expenses at $187830.0 in Q1 2026, $302900.0 in Q4 2025, and $502654.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 32,805.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187,830.00 |
| Mar 31, 2026 | 187,830.00 |
| Dec 31, 2025 | 302,900.00 |
| Dec 31, 2025 | 302,900.00 |
| Sep 30, 2025 | 502,654.00 |
| Sep 30, 2025 | 502,654.00 |
| Jun 30, 2025 | -13,914.00 |
| Jun 30, 2025 | -13,914.00 |
| Mar 31, 2025 | -183,350.00 |
| Mar 31, 2025 | -183,350.00 |
| Dec 31, 2024 | -934,660.00 |
| Dec 31, 2024 | -934,660.00 |
| Sep 30, 2024 | 596,542.00 |
| Sep 30, 2024 | 596,542.00 |
| Jun 30, 2024 | -91,010.00 |
| Jun 30, 2024 | -91,010.00 |
| Mar 31, 2024 | 126,689.00 |
| Mar 31, 2024 | 126,689.00 |
| Dec 31, 2023 | -35,140.00 |
| Dec 31, 2023 | -35,140.00 |